Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

New data demonstrated that long-acting cabotegravir was preferable to daily dolutegravir/lamivudine in treatment-naive people living with HIV.

Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

Patients with AD treated with dupilumab have a lower risk of various infections than those treated with methotrexate or cyclosporine.

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

Considering dual biologic therapy for psoriasis or eczema? Get a firsthand account of navigating insurance, potential side effects, and treatment outcomes.

Child mortality has been halved in the last 25 years. Building on this progress, new innovations in immunization are working ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid and advanced skin cancer. This FDA recap highlights recent approvals in April ...

Medicare may cover epidural steroid injections for pain management when the pain is severe, caused by specific conditions, and lasts over 4 weeks despite other treatment.

Discover a study where results suggest a statistically significant association between dupilumab and psoriasis, although the clinical impact may be limited.

The FDA has approved a 200 mg/mL autoinjector of belimumab (Benlysta) for at-home subcutaneous use in children aged 5 years and older with active lupus nephritis receiving standard therapy-marking the ...